ArticleBriefings in bioinformatics2025
IgRENE: integrating gene regulatory networks and drug ontologies towards selected modification of target gene's expression.
Article in Briefings in bioinformatics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
IgRENE is a web-based platform designed to integrate gene regulatory networks (GRNs) with drug-based regulatory data through a comprehensive, criteria-driven computational framework. The proposed tool provides a methodology for analyzing and identifying drugs along with their regulatory pathways, combining both upstream and downstream effects to assess the modulation of gene expression. This approach aids in prioritizing potential therapeutic compounds for more efficient further experimental validation and clinical testing. By consolidating gene-to-gene and drug-to-gene regulatory interactions within a unified interface, IgRENE provides researchers in drug discovery, systems biology, and precision medicine with a powerful tool that highlights drug candidates predicted to have a desired downstream effect on the expression of disease associated genes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.